Logo
x

Search

Subscribe Now

Pulmonary Disease

GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19

GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19

  • May 8, 2020
AstraZeneca's Breztri Aerosphere (PT010) and Bevespi Aerosphere Receive MHLW's Approval for Chronic Obstructive Pulmonary Disease in Japan

AstraZeneca's Breztri Aerosphere (PT010) and Bevespi Aerosphere Receive MHLW's Approval for Chronic Obstructive Pulmonary Disease...

  • June 19, 2019
Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)

    Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)

    • May 31, 2024
    Sanofi and Regeneron Report the US FDA’s Acceptance of sBLA for Dupixent with Priority Review to Treat COPD with Type 2 Inflammation

      Sanofi and Regeneron Report the US FDA’s Acceptance of sBLA for Dupixent with Priority Review to Treat COPD with Type 2 Inflammati...

      • February 23, 2024
      The US FDA Approves NuvoAir’s Air Next Spirometer for In-Home Use

        The US FDA Approves NuvoAir’s Air Next Spirometer for In-Home Use

        • January 31, 2024
        Renovion Concludes Patient Recruitment in the P-II (CLIMB) Trial of ARINA-1 for Bronchiectasis

          Renovion Concludes Patient Recruitment in the P-II (CLIMB) Trial of ARINA-1 for Bronchiectasis

          • January 12, 2024
          Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

            Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

            • December 4, 2023
            Sanofi Reports Results for Dupixent in P-III Trial for the Treatment of Patients with COPD

              Sanofi Reports Results for Dupixent in P-III Trial for the Treatment of Patients with COPD

              • November 27, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.